Related references
Note: Only part of the references are listed.Survival of cancer survivors with a new pancreatic cancer diagnosis
Sandi L. Pruitt et al.
CANCER MEDICINE (2023)
Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer
James T. Topham et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Circulating tumour DNA: a challenging innovation to develop precision onco-surgery in pancreatic adenocarcinoma
Daniel Pietrasz et al.
BRITISH JOURNAL OF CANCER (2022)
Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
Alison M. Schram et al.
CANCER DISCOVERY (2022)
A Breakthrough Brought about by Targeting KRASG12C: Nonconformity Is Punished
Wenjuan Ning et al.
CANCERS (2022)
Impact of the COVID-19 Pandemic on Management of Patients with Metastatic Pancreatic Ductal Adenocarcinoma in the United States
Ravi Paluri et al.
ONCOLOGIST (2022)
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
Jeanne Tie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma
Daniel J. Renouf et al.
NATURE COMMUNICATIONS (2022)
Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In?
Erica S. Tsang et al.
CLINICAL CANCER RESEARCH (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Molecular pro fi ling of ctDNA in pancreatic cancer: Opportunities and challenges for clinical application
L. Sivapalan et al.
PANCREATOLOGY (2021)
Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma
Gehan Botrus et al.
ONCOLOGIST (2021)
Interpreting Sequence Variation in PDAC-Predisposing Genes Using a Multi-Tier Annotation Approach Performed at the Gene, Patient, and Cohort Level
Michael T. Zimmermann et al.
FRONTIERS IN ONCOLOGY (2021)
Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers
Hitomi Sumiyoshi Okuma et al.
FRONTIERS IN ONCOLOGY (2021)
Clinical and cost outcomes following genomics-informed treatment for advanced cancers
Deirdre Weymann et al.
CANCER MEDICINE (2021)
Management of Patients with Pancreatic Ductal Adenocarcinoma in the Real-Life Setting: Lessons from the French National Hospital Database
Christelle de la Fouchardiere et al.
CANCERS (2021)
Recent advances in precision medicine for pancreatic ductal adenocarcinoma
Hiromitsu Hayashi et al.
ANNALS OF GASTROENTEROLOGICAL SURGERY (2021)
Clinical Implications of Pre- and Postoperative Circulating Tumor DNA in Patients with Resected Pancreatic Ductal Adenocarcinoma
Takuro Yamaguchi et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
Michael J. Pishvaian et al.
LANCET ONCOLOGY (2020)
Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer
Marta Toledano-Fonseca et al.
CANCERS (2020)
Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer
Jiahong Jiang et al.
FRONTIERS IN ONCOLOGY (2020)
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
Yoshiaki Nakamura et al.
NATURE MEDICINE (2020)
Risk of Developing Pancreatic Cancer in Patients with Chronic Pancreatitis
Miroslav Vujasinovic et al.
JOURNAL OF CLINICAL MEDICINE (2020)
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
Claudio Luchini et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer
Vincent P. Groot et al.
CLINICAL CANCER RESEARCH (2019)
NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma
Martin R. Jones et al.
CLINICAL CANCER RESEARCH (2019)
Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood
Maryam A. L. Eissa et al.
CLINICAL EPIGENETICS (2019)
Circulating tumor DNA use in a community oncology practice
Erin D. Chamberlain et al.
TRANSLATIONAL CANCER RESEARCH (2019)
Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer
B. Lee et al.
ANNALS OF ONCOLOGY (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion
E. M. O'Reilly et al.
ANNALS OF ONCOLOGY (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
KRAS Mutant Allele Fraction in Circulating Cell-Free DNA Correlates With Clinical Stage in Pancreatic Cancer Patients
Zhe-Ying Wang et al.
FRONTIERS IN ONCOLOGY (2019)
NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer
Christoph Heining et al.
CANCER DISCOVERY (2018)
Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer
S. Kruger et al.
ANNALS OF ONCOLOGY (2018)
Analytical validation of a comprehensive 500-gene ctDNA panel designed for immuno-oncology and DNA damage research
Elena Helman et al.
CANCER RESEARCH (2018)
Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients
Gahee Park et al.
SCIENTIFIC REPORTS (2018)
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial
Kyaw L. Aung et al.
CLINICAL CANCER RESEARCH (2018)
Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma
Vincent P. Groot et al.
ANNALS OF SURGERY (2018)
Imaging modalities in the diagnosis of pancreatic adenocarcinoma: A systematic review and meta- analysis of sensitivity, specificity and diagnostic accuracy
James Toft et al.
EUROPEAN JOURNAL OF RADIOLOGY (2017)
Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers
Joshua D. Cohen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer
Patricia Adamo et al.
ONCOTARGET (2017)
The cost and cost trajectory of whole-genome analysis guiding treatment of patients with advanced cancers
Deirdre Weymann et al.
MOLECULAR GENETICS & GENOMIC MEDICINE (2017)
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer
Marzia Del Re et al.
SCIENTIFIC REPORTS (2017)
Cost analysis of whole genome sequencing in German clinical practice
Marika Ploethner et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2017)
Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition
Nikolaos Ioanou et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer
Francesca Riva et al.
MOLECULAR ONCOLOGY (2016)
KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control study
Florence Le Calvez-Kelm et al.
ONCOTARGET (2016)
Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer
Julie Earl et al.
BMC CANCER (2015)
Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer
Hideaki Kinugasa et al.
CANCER (2015)
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell et al.
NATURE (2015)
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
Richard B. Lanman et al.
PLOS ONE (2015)
Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer
Erina Takai et al.
SCIENTIFIC REPORTS (2015)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Pancreatic ductal adenocarcinoma: Risk factors, screening, and early detection
Andrew E. Becker et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Circulating mutant DNA to assess tumor dynamics
Frank Diehl et al.
NATURE MEDICINE (2008)
Detection and quantification of mutations in the plasma of patients with colorectal tumors
F Diehl et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)